) recently reported results for the first quarter of 2013.
Revenues fell 8.2% year over year to approximately $1.1 billion
due to generic erosion of Keppra and a delayed allergy
All growth rates mentioned below are on a year-on-year basis
and at CER.
While Cimzia (Crohn's disease and rheumatoid arthritis) sales
increased 27% in the reported quarter, Vimpat (epilepsy) sales
increased 16%. Neupro, which is marketed as a treatment for
Parkinson's disease (PD) and restless legs syndrome (RLS),
delivered sales growth of 37%.
However, sales of Keppra, another epilepsy treatment, declined
22%. Sales were hurt by generic competition in the US and
Vimpat as monotherapy met its primary endpoint in a phase III
study on epilepsy in the US. The company intends to file for US
approval in the second half of 2013.
For the PD and RLS indications, Neupro received regulatory
approval in Japan in Dec 2012. UCB's partner, Otsuka
Pharmaceuticals, has launched Neupro in Japan.
For the RA indication, Cimzia was approved in Japan in Dec
2012. UCB's partner
Astellas Pharma, Inc.
) has launched the drug in Japan.
UCB is currently looking to get Cimzia's label expanded for
the treatment of active psoriatic arthritis and active axial
spondyloarthritis in the US, EU and other regions.
The company maintained its previously issued guidance of €3.4
million of revenues for 2013 and earnings per share in the band
UCB carries a Zacks Rank #1 (Strong Buy). Other companies like
Catalyst Pharmaceutical Partners Inc.
Onyx Pharmaceuticals, Inc.
) also carry a Zacks Rank #1.
ASTELLAS PHARMA (ALPMY): Get Free Report
CATALYST PHARMA (CPRX): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.